YagoLuisNietoMD

Oncology • Houston, TX

Hematologic Oncology

Professor of Medicine, University of Texas

Join to view full profile

Dr. Nieto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nieto's full profile

Already have an account?

Office
MD Anderson Cancer Center
1515 Holcombe Blvd
Houston, TX 77030

Summary

Dr. Yago Nieto is an oncologist in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Universidad de Navarra School of Medicine and has been in practice 27 years. He specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation and lymphoma.

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 1996 - 1999
Universidad de Navarra Faculty of MedicineClass of 1990

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2027
TN State Medical License 2024 - 2026
WA State Medical License 2024 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
MS State Medical License 2024 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2006 - 2025
CO State Medical License 1999 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors Start of enrollment: 2009 Jun 02
Completed
Phase 2
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Start of enrollment: 2012 Oct 25
Completed
Phase 1, Phase 2
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Start of enrollment: 2015 Apr 01
Completed
Phase 2
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Start of enrollment: 2016 Jun 01
Withdrawn
Phase 1, Phase 2
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Start of enrollment: 2017 Jun 01
Withdrawn
Phase 2
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2017 Oct 10
Completed
Phase 2
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma Start of enrollment: 2017 Apr 03
Active, not recruiting
Phase 2
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant Start of enrollment: 2019 Sep 13
Active, not recruiting
Phase 1
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Start of enrollment: 2020 Jul 18
Active, not recruiting
Phase 1, Phase 2
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Start of enrollment: 2021 Oct 29
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors.
Jenny J Xiang, Matthew T Campbell, Shi-Ming Tu, John Araujo, Yago Nieto
Clinical Genitourinary Cancer. 2024-12-01
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Jeremy Ramdial, Ruitao Lin, Peter F Thall, Benigno C Valdez, Chitra Hosing
Bone Marrow Transplantation. 2024-12-01
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
Curtis Marcoux, Sarah Pasyar, Denái R Milton, Hina N Khan, Mark R Tanner
British Journal of Haematology. 2024-11-28

Journal Articles

Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs
Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature

Abstracts/Posters

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Yago Nieto, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Join now to see all

Lectures

Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Pano/GBM plus ASCT Deemed Safe and Effective in High-Risk or Rel/Ref MMFebruary 24th, 2023
22 Research Highlights from the Past YearDecember 19th, 2022
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate ProgressNovember 15th, 2022
Join now to see all